Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iosefamic Acid SCHEMBL38639 | 0.98 | TSHR (0.55) | TSHRMAPK1LMNASMN1; SMN2HDAC1 | |
| Iosefamic Acid SCHEMBL29648519 | 0.98 | TSHR (0.55) | TSHRMAPK1LMNASMN1; SMN2HDAC1 | |
| Iosefamic Acid SCHEMBL29400390 | 0.98 | TSHR (0.55) | TSHRMAPK1LMNASMN1; SMN2HDAC1 | |
| SCHEMBL8610051 | 0.86 | LMNA (0.42) | TSHRMAPK1LMNASMN1; SMN2 | |
| SCHEMBL30881052 | 0.86 | LMNA (0.42) | TSHRMAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL11632856 | 0.85 | MAPK1 (0.46) | TSHRMAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9716687 | 0.84 | TSHR (0.52) | TSHRMAPK1LMNASMN1; SMN2HDAC1 | |
| Iocarmic Acid SCHEMBL29886627 | 0.84 | SMN1; SMN2 (0.65) | TSHRMAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3833534 | 0.84 | LMNA (0.40) | TSHRMAPK1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL11406813 | 0.82 | LMNA (0.47) | TSHRMAPK1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683579-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | Yeung, Jeffrey E. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250170279-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250170280-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| WO-2024158529-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | YEUNG JEFFREY E (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| CN-110402137-B | Silica body delivery system for targeted activation of CD44 molecule, and preparation method and application thereof | 北京茵诺医药科技有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-110545799-B | Recombinant bionic nano-carrier delivery system for targeting activation of CD44 molecule, and preparation method and application thereof | 北京茵诺医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-110545800-B | Nano-calcium carrier delivery system for targeting activation of CD44 molecule, and preparation method and application thereof | 北京茵诺医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-110545793-B | Metal framework compound nano-carrier delivery system for targeting activation of CD44 molecule, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| JP-2691073-B2 | — | — | 1997-12-17 | — | — | JP | claimed |
| US-5660814-A | Iodinated paramagnetic chelates, and their use as contrast agents | DIBRA S.P.A. (IT) | 1997-08-26 | — | — | US | claimed |
| EP-0767779-A1 | ALPHA-(CYCLOALKYL, ARYL AND ARALKYL)SUBSTITUTED POLYIODINATED AROYLOXY COMPOUNDS | NanoSystems L.L.C. (US) | 1997-04-16 | — | — | EP | claimed |
| EP-0703790-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.p.A. (IT) | 1996-04-03 | — | — | EP | claimed |
| WO-1996000211-A1 | ALPHA-(CYCLOALKYL, ARYL AND ARALKYL)SUBSTITUTED POLYIODINATED AROYLOXY COMPOUNDS | NANOSYSTEMS L.L.C. (US) | 1996-01-04 | — | — | WO | claimed |
| EP-0644740-A4 | STEREOTACTIC MAMMOGRAPHY AND NEEDLE BIOPSY TABLE WITH CCD IMAGING SYSTEM. | THERMOTREX CORP LORAD CORP (US) | 1995-11-02 | — | — | EP | claimed |
| EP-0644740-A1 | STEREOTACTIC MAMMOGRAPHY AND NEEDLE BIOPSY TABLE WITH CCD IMAGING SYSTEM | THERMOTREX CORPORATION (US) | 1995-03-29 | — | — | EP | claimed |
| WO-1994027644-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.P.A. (IT) | 1994-12-08 | — | — | WO | claimed |
| WO-1993011706-A1 | STEREOTACTIC MAMMOGRAPHY AND NEEDLE BIOPSY TABLE WITH CCD IMAGING SYSTEM | PELLEGRINO ANTHONY J (US) | 1993-06-24 | — | — | WO | claimed |
| EP-0050457-A1 | Radiopaque cyanoacrylate compositions | BioNexus, Inc. (US) | 1982-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | CD44, LDLR, PLAUR | TSHR 3170/4885MAPK1 3939/4885LMNA 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.